| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_69ece09bafee7e0c49d1f7951a3faa2c |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6889
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6875
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D221-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6867
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6855
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6849 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D221-14 |
| filingDate |
2006-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd4cd83f6ae009e2c5aaf891baff00d2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a1f4f82a527638d5a7240acadd68b71c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c298fbbe03aa3b21db3b19a00c2ae982
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b5775f99a61ef698b4c9a2302198c257 |
| publicationDate |
2008-08-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1954317-A2 |
| titleOfInvention |
Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use |
| abstract |
The invention relates to bis 1, 8 naphthalimide compounds including antibody drag conjugate (ADC) compounds represented by Formula (I) : where one or more 1, 8 bis-naphthalimide drug moieties (D) having Formulas (IIa) and (IIb) are covalently linked, through the wavy line, by a linker (L) to an antibody (Ab). The invention also relates to heterocyclic-substituted 1, 8 bis-naphthalimide compounds having Formula (XV). The invention also relates to pharmaceutical compositions comprising an effective amount of a Formula (I) ADC or Formula (XV) heterocyclic-substituted 1, 8 bis-naphthalimide compound for treatment of hyperproliferative disorders and other disorders. The invention also relates to methods for killing or inhibiting the proliferation of tumor cells or cancer cells including administering to a patient an effective amount of a Formula (I) ADC or Formula (XV) compound. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-101364941-B |
| priorityDate |
2005-11-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |